Vaxcyte (PCVX) Projected to Post Quarterly Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is expected to announce its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.46) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Vaxcyte Stock Up 2.1%

PCVX opened at $58.51 on Monday. Vaxcyte has a 52 week low of $27.66 and a 52 week high of $84.01. The stock has a market cap of $7.66 billion, a PE ratio of -12.09 and a beta of 1.33. The business has a 50 day moving average of $50.05 and a 200-day moving average of $43.01.

Insider Transactions at Vaxcyte

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of Vaxcyte stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the sale, the insider owned 23,928 shares in the company, valued at approximately $1,117,198.32. The trade was a 28.94% decrease in their position. The SEC filing for this sale provides additional information. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC lifted its holdings in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares during the last quarter. CIBC Private Wealth Group LLC lifted its stake in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the period. Danske Bank A S bought a new position in Vaxcyte during the 3rd quarter valued at about $76,000. Finally, Virtus Advisers LLC purchased a new stake in shares of Vaxcyte during the 4th quarter valued at about $161,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on PCVX shares. Guggenheim reissued a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Needham & Company LLC lifted their price target on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.